{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-041918","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2026-09-09T14:10:13+00:00","discovered_at":"2026-09-09T14:11:00.294879+00:00","generated_at":"2026-09-09T14:11:09.292966+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aspire-Lakewood (ASBP) approves $10M buyback; DCSC 2025 revenue $209.5M, EBITDA $22.3M","bullets":["Name changed to Aspire-Lakewood Holdings, Inc. effective Sept 8, 2026; ticker remains ASBP.","Board authorized $10M common stock repurchase program effective Sept 9, 2026.","DCSC FY2025 revenue ~$209.5M, Adjusted EBITDA $22.3M; H1 2026 revenue $103.9M, EBITDA $10.5M.","~1.5M shares outstanding as of Sept 8, 2026; 2025 Adjusted EBITDA ~$15.00 per share.","CEO cites strong cash flow and undervaluation; buyback may be open market or private transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-041918","json":"https://secwatch.observer/filing/0001493152-26-041918.json","markdown":"https://secwatch.observer/filing/0001493152-26-041918.md","text":"https://secwatch.observer/filing/0001493152-26-041918.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/0001493152-26-041918-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226041918/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T14:11:09.292966+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}